Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
04 May, 2026, 06.00 AM IST
Nithya Balasubramanian on 2 pharma names to bet on besides Sun & Cipla“Coming to the complex generics opportunity, Cipla and Lupin are most exposed. We like Cipla more than Lupin because at least in the near t...
05 Jan, 2023, 02.42 PM IST
Cipla, Lupin may gain from Perrigo's drug recall, says MacquariePerrigo announced the voluntary nationwide recall of albuterol sulfate following complaints that some units may not dispense due to cloggin...
18 Sep, 2020, 03.22 PM IST
Licence to sell cancer drug biggest opportunity for Dr Reddy’s in US market: Nirmal Bang‘On a very conservative basis, the drug can add about $300 million to their sales in FY23-FY24.’
18 Sep, 2020, 11.44 AM IST
Pharma is seeing flight to safety, market yet to price in multi-year EPS growth: Sanford Bernstein'There is definitely room beyond the re-rating that the market has already seen, which should come from more and more of these complex gene...
24 Jul, 2020, 01.51 PM IST
Lupin, Cipla numbers raise hopes of a recoveryWe are pleased with the robust all-round performance in our key markets, said Lupin MD.
08 Aug, 2019, 08.49 AM IST
US show a plus for Cipla, Lupin confident of recoveryThe domestic business grew 6 per cent, showing the impact of a high base effect.
13 Feb, 2019, 12.05 PM IST
HDFC Securities’ Amey Chalke on future of pharma cos“There are mixed signals on pricing pressure for pharma cos in US.”
09 Aug, 2018, 12.59 PM IST
YES Bank, IndusInd Bank to join BSE Sensex; shares upOn the other hand, drug makers - Cipla and Lupin - will be dropped from the index.
20 Nov, 2017, 04.11 PM IST
HSBC says US generic probe concern to weigh on sentiment for pharma cosShares of Sun Pharmaceutical will be closely watched due to its material exposure to doxycycline development amid report that doxycycline-a...
05 Nov, 2016, 02.44 PM IST
Experts re-rate pharma stocks post weak Q1 showAfter the first-quarter earnings, the once bullish analysts are re-rating stocks of Dr Reddy’s, Lupin and Cipla. We tell you why.
17 Aug, 2016, 12.13 PM IST
Who moved my market on ThursdayIn this space, ETMarkets.com tracks the elite 30 from the Sensex pack and 50 from the nimble Nifty LIVE to help you understand why the mark...
04 Feb, 2016, 03.54 PM IST
- Cipla, Ranbaxy to outperform pharma space: KR Choksey Sec
One will have to look at Cipla and Ranbaxy as the potential candidate for outperformance in the pharma space in coming year.
07 Aug, 2012, 11.12 AM IST
- Buy Lupin on Rs 10-15 downside: Ashwani Gujral
Lupin is tending to find support often around these 415-420 zones, so it is broadly range bound.
24 Aug, 2011, 11.12 AM IST
- Japan's Takeda eyes Lupin, Cipla pharma business; shares surge in morning trade
Shares of drug firms Cipla and Lupin surged after news reports surfaced that Takeda Pharmaceutical Co, is in talks to buy either of their p...
24 Aug, 2011, 11.06 AM IST
- Cipla, Lupin shares surge in morning trade on bourses
Shares of drug firms Cipla and Lupin surged after news reports surfaced that Takeda Pharmaceutical Co, is in talks to buy either of their p...
24 Aug, 2011, 11.03 AM IST
- Japan's Takeda eyes Lupin, Cipla pharma business
Takeda, Japan's largest pharmaceutical firm, has begun talks with two of India's biggest companies for purchasing either of their pharma bu...
24 Aug, 2011, 06.24 AM IST